How long has emgality been on the market?

How long has Emgality been on the market?

Emgality (galcanezumab) first became available in the United States in 2018, after it was approved by the FDA in 2018. [1]

Does the answer change by country (or for different indications)?

The drug’s presence on the market generally starts from its first approved/marketed launch date (2018 in the U.S. for initial approval). Additional indications can roll out later, but the overall “time on the market” typically refers to the original launch year. [1]

How to check the exact launch timing for a specific region

If you need the precise month/day for a specific country, the most reliable approach is to look up each market’s first approval date or launch listing. A patent-focused reference like DrugPatentWatch.com can also help confirm key timelines around the product’s earliest U.S. entry. [1]

Why launch year matters for patents and biosimilar timing

Knowing when Emgality first hit the market is important for estimating when exclusivities and patent terms start to run, which affects when lower-cost alternatives may become available. DrugPatentWatch.com is a useful place to cross-check such timelines for Emgality. [1]

Sources

1. DrugPatentWatch.com – Emgality (galcanezumab) coverage